Benjamin J Wheeler1,2, Olivia J Collyns3, Renee A Meier4, Zara L Betts4, Chris Frampton5, Carla M Frewen2, Barbara Galland2, Niranjala M Hewapathirana1, Shirley D Jones2, Denis S H Chan3, Anirban Roy6, Benyamin Grosman6, Natalie Kurtz6, John Shin6, Robert A Vigersky6, Martin I de Bock7,8,9. 1. Southern District Health Board, 201 Great King Street, Dunedin, 9016, New Zealand. 2. Department of Women's and Children's Health, Dunedin School of Medicine, University of Otago, 201 Great King Street, Dunedin, 9016, New Zealand. 3. Canterbury District Health Board, 2 Riccarton Avenue, Christchurch Central City, Christchurch, 8011, New Zealand. 4. Christchurch Clinical Studies Trust, Level 4/264 Antigua Street, Christchurch Central City, Christchurch, 8011, New Zealand. 5. Departent Paediatrics, University of Otago, Terrace House, 4 Oxford Terrace, Christchurch, 8011, New Zealand. 6. Medtronic, 18000 Devonshire Street, Northridge, CA, 91325, USA. 7. Canterbury District Health Board, 2 Riccarton Avenue, Christchurch Central City, Christchurch, 8011, New Zealand. Martin.debock@otago.ac.nz. 8. Departent Paediatrics, University of Otago, Terrace House, 4 Oxford Terrace, Christchurch, 8011, New Zealand. Martin.debock@otago.ac.nz. 9. Christchurch Hospital, 2 Riccarton Ave, P.O. Box 3245, Christchurch, 8140, New Zealand. Martin.debock@otago.ac.nz.
Abstract
BACKGROUND: Automated insulin delivery aims to lower treatment burden and improve quality of life as well as glycemic outcomes. METHODS: We present sub-study data from a dual-center, randomized, open-label, two-sequence crossover study in automated insulin delivery naïve users, comparing Medtronic MiniMed® Advanced Hybrid Closed-Loop (AHCL) to Sensor Augmented Pump therapy with Predictive Low Glucose Management (SAP + PLGM). At the end of each 4-week intervention, impacts on quality of life, sleep and treatment satisfaction were compared using seven age-appropriate validated questionnaires given to patients or caregivers. RESULTS: 59/60 people completed the study (mean age 23.3 ± 14.4yrs). Statistically significant differences favoring AHCL were demonstrated in several scales (data shown as mean ± SE). In adults (≥ 18yrs), technology satisfaction favored AHCL over PLGM as shown by a higher score in the DTSQs during AHCL (n = 28) vs SAP + PLGM (n = 29) (30.9 ± 0.7 vs 27.9 ± 0.7, p = 0.004) and DTSQc AHCL (n = 29) vs SAP + PLGM (n = 30) (11.7 ± 0.9 vs 9.2 ± 0.8, p = 0.032). Adolescents (aged 13-17yrs) also showed a higher DTSQc score during AHCL (n = 16) versus SAP + PLGM (n = 15) (14.8 ± 0.7 vs 12.1 ± 0.8, p = 0.024). The DTQ "change" score (n = 59) favored AHCL over SAP + PLGM (3.5 ± 0.0 vs 3.3 ± 0.0, p < 0.001). PSQI was completed in those > 16 years (n = 36) and demonstrated improved sleep quality during AHCL vs SAP + PLGM (4.8 ± 0.3 vs 5.7 ± 0.3, p = 0.048) with a total score > 5 indicating poor quality sleep. CONCLUSION: These data suggest that AHCL compared to SAP + PLGM mode has the potential to increase treatment satisfaction and improve subjective sleep quality in adolescents and adults with T1D.
BACKGROUND: Automated insulin delivery aims to lower treatment burden and improve quality of life as well as glycemic outcomes. METHODS: We present sub-study data from a dual-center, randomized, open-label, two-sequence crossover study in automated insulin delivery naïve users, comparing Medtronic MiniMed® Advanced Hybrid Closed-Loop (AHCL) to Sensor Augmented Pump therapy with Predictive Low Glucose Management (SAP + PLGM). At the end of each 4-week intervention, impacts on quality of life, sleep and treatment satisfaction were compared using seven age-appropriate validated questionnaires given to patients or caregivers. RESULTS: 59/60 people completed the study (mean age 23.3 ± 14.4yrs). Statistically significant differences favoring AHCL were demonstrated in several scales (data shown as mean ± SE). In adults (≥ 18yrs), technology satisfaction favored AHCL over PLGM as shown by a higher score in the DTSQs during AHCL (n = 28) vs SAP + PLGM (n = 29) (30.9 ± 0.7 vs 27.9 ± 0.7, p = 0.004) and DTSQc AHCL (n = 29) vs SAP + PLGM (n = 30) (11.7 ± 0.9 vs 9.2 ± 0.8, p = 0.032). Adolescents (aged 13-17yrs) also showed a higher DTSQc score during AHCL (n = 16) versus SAP + PLGM (n = 15) (14.8 ± 0.7 vs 12.1 ± 0.8, p = 0.024). The DTQ "change" score (n = 59) favored AHCL over SAP + PLGM (3.5 ± 0.0 vs 3.3 ± 0.0, p < 0.001). PSQI was completed in those > 16 years (n = 36) and demonstrated improved sleep quality during AHCL vs SAP + PLGM (4.8 ± 0.3 vs 5.7 ± 0.3, p = 0.048) with a total score > 5 indicating poor quality sleep. CONCLUSION: These data suggest that AHCL compared to SAP + PLGM mode has the potential to increase treatment satisfaction and improve subjective sleep quality in adolescents and adults with T1D.
Authors: Olivia J Collyns; Renee A Meier; Zara L Betts; Denis S H Chan; Chris Frampton; Carla M Frewen; Niranjala M Hewapathirana; Shirley D Jones; Anirban Roy; Benyamin Grosman; Natalie Kurtz; John Shin; Robert A Vigersky; Benjamin J Wheeler; Martin I de Bock Journal: Diabetes Care Date: 2021-02-12 Impact factor: 19.112
Authors: Grace C Macaulay; Barbara C Galland; Sara E Boucher; Esko J Wiltshire; Jillian J Haszard; Angela J Campbell; Stephanie M Black; Claire Smith; Dawn Elder; Benjamin J Wheeler Journal: Sleep Date: 2020-02-13 Impact factor: 5.849
Authors: Alessandro Bisio; Linda Gonder-Frederick; Ryan McFadden; Daniel Cherñavvsky; Mary Voelmle; Michael Pajewski; Pearl Yu; Heather Bonner; Sue A Brown Journal: J Diabetes Sci Technol Date: 2021-01-15